Could the Hurricane Energy share price be the bargain of the year?

G A Chester weighs up the potential of exciting oil stock Hurricane Energy plc (LON:HUR) and a pharma firm aiming to rise like a phoenix.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s no shortage of loss-making-but-high-potential companies on the stock market. Oil explorers and developers and pharmaceuticals and medical technology firms offer the prospect of particularly big gains for investors who identify the right company at the right price.

Of course, this is easier said than done. For every millionaire-maker there are dozens of duds. Today, I’m weighing up the potential of oil stock Hurricane Energy (LSE: HUR) and pharma player Circassia (LSE: CIR), which released its annual results today.

Collapse

Heavily backed by cornerstone investors Neil Woodford and his protégé at former employer Invesco, Circassia pursued the development of a whole platform of allergy treatments that were said to build immunity quicker than existing remedies and without the risk of anaphylactic shocks. When its lead cat allergy failed a Phase III study, the entire programme collapsed.

At the height of investor confidence, Circassia was a member of the FTSE 250 index, with a share price of 350p and market capitalisation of over £1bn. Today, it’s on the AIM market, its share price is 31.5p (down a little on the back of its results) and its market cap is £118m. Its accounts show an accumulated loss of over half-a-billion quid.

However, it now has a small portfolio of revenue-generating products, including via a commercial collaboration with AstraZeneca, which has also become a 19% shareholder in Circassia. Could the stock be set to rise like a phoenix?

Recovery?

Just over a year ago, I wrote that I wouldn’t touch Circassia with a bargepole, noting also a 5.42% short position in the stock held by hedge fund Mangrove.

Today’s results showed a £37.2m operating loss on revenue of £48.3m. There are signs of promising revenue growth, and with the share price much lower than a year ago, the valuation picture has improved.

However, continued losses are forecast into next decade and Mangrove has maintained its chunky short position. I’m not convinced the risk/reward proposition with Circassia is compelling, and so continue to see it as a stock to avoid at this stage.

Share price to double?

By contrast, when I last wrote about Hurricane Energy (November 2017), I felt its progress to date, potential to become a major player in the West of Shetland region, and share price of 26.75p (market cap £524m) represented an attractive risk/reward proposition. The shares are currently trading at around 47p (market cap £921m), but I continue to see a compelling investment opportunity.

The company is on track to deliver first oil from its 100%-owned Lancaster discovery before the end of June. Planned initial production is 17,000 barrels a day, and management expects to generate over $200m in operating cash flow on a full-year run-rate basis at a $60 a barrel Brent oil price.

Meanwhile, a 50% farm-in to its Warwick and Lincoln fields by Spirit Energy, providing up to $387m, has enabled an acceleration of activity, including the drilling of three wells this year, one of which was spudded last month.

If we see the company successfully executing on this year’s work programme, I think the share price could easily double from its current level. And with total 2P reserves and 2C contingent resources across the asset base standing at 2.3bn barrels net to Hurricane, there’s potential for the value of the company to continue increasing as time goes on.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Dividend Shares

Will the Diageo share price crash again in 2026?

The Diageo share price has crashed 35.6% over one year, making it one of the FTSE 100's worst performers in…

Read more »

Investing Articles

Is Alphabet still one of the best shares to buy heading into 2026?

The best time to buy shares is when other investors are seeing risks. Is that the case with Google’s parent…

Read more »

Investing Articles

Could the Barclays share price be the FTSE 100’s big winner in 2026?

With OpenAI and SpaceX considering listing on the stock market, could investment banking revenues push the Barclays share price higher…

Read more »

Investing Articles

Will the Nvidia share price crash in 2026? Here are the risks investors can’t ignore

Is Nvidia’s share price in danger in 2026? Stephen Wright outlines the risks – and why some might not be…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Growth Shares

I asked ChatGPT how much £10,000 invested in Lloyds shares 5 years ago is worth today? But it wasn’t very helpful…

Although often impressive, artificial intelligence has its flaws. James Beard found this out when he used it to try and…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Did ChatGPT give me the best FTSE stocks to buy 1 year ago?

ChatGPT can do lots of great stuff, but is it actually any good at identifying winning stocks from the FTSE…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Who will be next year’s FTSE 100 Christmas cracker?

As we approach Christmas 2025, our writer identifies the FTSE 100’s star performer this year. But who will be number…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

I asked ChatGPT for an 8%-yielding passive income portfolio of dividend shares and it said…

Mark Hartley tested artificial intelligence to see if it understood how to build an income portfolio from dividend shares. He…

Read more »